The relationship between physicians and pharmacy benefit managers continues to change. A goal of Prescription Solutions' Brian Solow, MD, is to foster a collaborative approach to working with physicians, to ultimately deliver better care to patients.
During his tenure with Bristol Park Medical Group, a physician-owned primary care group in Irvine, he participated on multiple leadership committees while maintaining a family medicine practice. Over the years, Dr. Solow has gained knowledge of the PBM industry as a member of the national pharmacy and therapeutics committees of various PBMs.
"I reach out to doctors and find out how we can become their partners and not interfere with their practices," Dr. Solow says. "We need them to recognize the true value of the PBM because a lot of physicians just see PBMs as another piece of the insurance puzzle. We know we can target the consumer, and the consumer can target the doctor. If we can get both parties onboard, we'll have better success implementing medi cation therapy management [MTM] and other clinical programs."
Q. What is your biggest challenge with managing pharmaceutical benefits?
We want them to understand that we are not trying to limit their utilization of medications, nor are we trying to limit choices, but rather are promoting the appropriateness of their prescription medications with a focus on the clinical quality. It's important that all stakeholders in the healthcare system work together to help patients lead healthy, productive lives.
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen